Microbot Medical (MBOT) Earns Buy Rating from Analysts at Ladenburg Thalmann Financial Services

Ladenburg Thalmann Financial Services assumed coverage on shares of Microbot Medical (NASDAQ:MBOT) in a research note issued to investors on Wednesday, MarketBeat reports. The brokerage issued a buy rating and a $1.75 price target on the biotechnology company’s stock.

Microbot Medical (NASDAQ MBOT) opened at $1.04 on Wednesday. Microbot Medical has a 12-month low of $1.00 and a 12-month high of $9.94. The firm has a market capitalization of $38.66, a P/E ratio of -1.51 and a beta of -0.39.

In other news, Director Yoseph Bornstein sold 42,132 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $1.01, for a total transaction of $42,553.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 272,990 shares of company stock worth $291,894 over the last ninety days. 31.83% of the stock is owned by insiders.

An institutional investor recently bought a new position in Microbot Medical stock. Sabby Management LLC bought a new position in shares of Microbot Medical Inc (NASDAQ:MBOT) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,285,351 shares of the biotechnology company’s stock, valued at approximately $1,825,000. Sabby Management LLC owned 2.92% of Microbot Medical as of its most recent SEC filing. Institutional investors own 4.67% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Microbot Medical (MBOT) Earns Buy Rating from Analysts at Ladenburg Thalmann Financial Services” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/04/microbot-medical-mbot-earns-buy-rating-from-analysts-at-ladenburg-thalmann-financial-services.html.

Microbot Medical Company Profile

Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply